Tag: Aeson
CARMAT achieves a structuring year in 2023 by reaching the milestone of 50 implantations of the Aeson® artificial heart and presents its development prospects – 01/15/2024 at 07:05
50 patients have benefited from CARMAT’s Aeson® artificial heart since the first implantation in 2013 Aeson® establishes itself as an essential breakthrough innovation in the treatment of advanced…
CARMAT announces a software improvement to significantly strengthen the safety profile of its Aeson® artificial heart – 12/28/2023 at 6:00 p.m.
Stéphane Piat, Managing Director of CARMAT, said: “In all industries, electronic components are potentially subject to failure because their production perfection is almost impossible to achieve. It was important to…
Carmat: first implantation of the Aeson artificial heart
(AOF) – Carmat announces the first implantation of the Aeson artificial heart in a patient suffering from a tumor on the heart mass. For this patient, only complete surgical removal…
CARMAT: The first American clinical experience relating to the Aeson® total artificial heart published in the journal “Annals of Thoracic Surgery Short Reports” – 03/06/2023 at 07:00
The publication highlights the effectiveness of the device resulting from the combination of hemocompatibility and self-regulation Paris, March 6, 2023 – 7:00 CET CARMAT (FR0010907956, ALCAR), designer and developer of…
Carmat announces the effective resumption of implantations of its Aeson artificial heart – 2022-11-21 at 18:25
(AOF) – A medtech company, Carmat announces the effective resumption of the implantations of its Aeson artificial heart on a commercial basis. On October 25, Carmat announced that the notified…
CARMAT announces the effective resumption of implantations of its Aeson® artificial heart on a commercial basis – 2022-11-21 at 07:00
CARMAT (FR0010907956, ALCAR, PEA-PME eligible), designer and developer of Aeson®, the most advanced total artificial heart in the world, aimed at offering a therapeutic alternative to patients suffering from end-stage…
Carmat authorized to resume implantations of the Aeson artificial heart in the commercial context – 2022-10-25 at 09:30
(AOF) – The medtech Carmat has obtained the necessary regulatory authorizations to resume the implantations of the Aeson artificial heart in the commercial context. Notified Body Dekra approved all changes…
Carmat: 47.4ME in cash to finance the exit of Aeson
Read also (CercleFinance.com) – Due to the temporary suspension of the implantations of its Aeson artificial heart, CARMAT did not record any turnover during the 1st half of 2022. The…